China CDC

China CDC
http://www.chinacdc.cn/en/
No new digest content identified.

 

National Health Commission of the People’s Republic of China
http://en.nhc.gov.cn/
Selected Updates and Press Releases
Chinese health authority urges enhanced flu prevention
2019-11-22
Chinese health authorities at all levels have been required to enhance their flu prevention measures and health education for the upcoming flu season.

China looks to expand malaria aid in Africa
2019-11-21
China plans to expand its overseas malaria assistance to wider regions of Africa in the next three years after a trial program in Tanzania showed promising results, a senior official with the Chinese Center for Disease Control and Prevention said recently.

Gates foundation to further assist TB fight
2019-11-21
China’s top health authority has extended its cooperation with the Bill & Melinda Gates Foundation in fighting tuberculosis across the country, aiming at scaling up proven models for curbing the disease and piloting innovative approaches.

Li lauds gains in healthcare, drug reforms
2019-11-21
China will improve its mechanism for centralized pharmaceuticals procurement to provide better and more affordable healthcare services, the State Council decided at an executive meeting chaired by Premier Li Keqiang on Nov 20.

Announcements

Announcements

 

Paul G. Allen Frontiers Group [to 23 Nov 2019]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
No new digest content identified.

 

BMGF – Gates Foundation [to 23 Nov 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute [to 23 Nov 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 23 Nov 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
11.20.2019  |
T2 Biosystems Announces Granting of CE-Mark for T2Resistance™ Panel
The T2Resistance Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 23 Nov 2019]
http://cepi.net/
No new digest content identified.

 

Clinton Health Access Initiative, Inc. (CHAI) [to 23 Nov 2019]
https://clintonhealthaccess.org/about/
News & Press Releases
CHAI 990 Forms
Published November 21st, 2019

 

EDCTP [to 23 Nov 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.

 

Emory Vaccine Center [to 23 Nov 2019]
http://www.vaccines.emory.edu/
No new digest content identified.

 

European Medicines Agency [to 23 Nov 2019]
http://www.ema.europa.eu/ema/
News & Press Releases
No new digest content identified.

 

European Vaccine Initiative [to 23 Nov 2019]
http://www.euvaccine.eu/news-events
19 November 2019
EU-China vaccine collaboration seminar
EVI together with partners and sponsors from China organised a two-day vaccine collaboration workshop from 9-10 November in Chengdu, China.
Aim of the workshop was to facilitate the interaction between European and Chinese vaccine developers and to inform Chinese participants about applicable regulations and requirements for introducing vaccines from China into Europe and low- and middle income countries.

 

FDA [to 23 Nov 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
No new digest content identified.

 

Fondation Merieux [to 23 Nov 2019]
http://www.fondation-merieux.org/
News, Events
December 3 – 4, 2019 – Geneva (Switzerland)
Mérieux Foundation co-organized event
6th GTFCC Working Group on Oral Cholera Vaccine

20 – 22 Jan 2020
Mérieux Foundation co-organized event
Dengue pre-vaccination screening strategies workshop
Les Pensières Center for Global Health, Veyrier-du-Lac (France)

 

Gavi [to 23 Nov 2019]
https://www.gavi.org/
Latest news
Meet the newest ambassadors for immunisation: 10,000 Karachi schoolgirls  
Karachi, 22 November 2019 – 10,000 teenage girls gathered at Karachi’s PAF museum this week to learn leadership skills, receive training on basic healthcare and become ambassadors for immunisation as a major typhoid vaccination campaign continues in the city.
The ‘Ab Meri Bari Hai!’ (Now It’s My Turn!) event, run by the Kiran Sitara programme, brought together girls from 58 schools in the city, as well as representatives from government, WHO and Gavi, the Vaccine Alliance.
The girls were also addressed by Samina Baig, the first Pakistani woman to climb Mount Everest, Hajra Khan, Captain of the Pakistan Women’s football team, and Aamina Sheikh, actress and ambassador for the Pakistan Alliance for Girls Education.
A vaccination session for the new Typhoid Conjugate Vaccine (TCV) took place after the event, part of a major campaign that aims to vaccinate over 10 million children in Sindh province in two weeks to combat an extensively drug resistant typhoid outbreak…

Gavi congratulates the Global Polio Eradication Initiative for raising vital funds to tackle polio  
Critical pledging moment in Abu Dhabi showcases continued commitment to eradication
Geneva, 21 November 2019 – Gavi, the Vaccine Alliance has congratulated the Global Polio Eradication Initiative (GPEI) for raising vital funds towards its Polio Endgame Strategy 2019-2023 at a pledging event in Abu Dhabi, United Arab Emirates.
“I want to offer my congratulations to the Global Polio Eradication Initiative on receiving these critical political and financial commitments,” said Dr Seth Berkley, CEO of Gavi. “The world has made tremendous progress on polio in little under three decades, thanks in large part to the work led by GPEI and national governments. It is important that we have sufficient resources to ensure that we do not backslide and lose that progress. Polio will remain a threat until every child is protected against this crippling disease.”
In March 2019, the CEO of Gavi became a member of GPEI’s Polio Oversight Board, and in October 2019, the Alliance joined WHO, Rotary International, the United States Centers for Disease Control and Prevention (CDC), UNICEF, and the Bill & Melinda Gates Foundation as an official core partner. Gavi’s work strengthening routine immunisation programmes will be critical in the ongoing fight against polio…

 

GHIT Fund [to 23 Nov 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

 

Global Fund [to 23 Nov 2019]
https://www.theglobalfund.org/en/news/
News & Stories
No new digest content identified.

 

Hilleman Laboratories [to 23 Nov 2019]
http://www.hillemanlabs.org/
No new digest content identified.

 

Human Vaccines Project [to 23 Nov 2019]
http://www.humanvaccinesproject.org/media/press-releases/
Press Releases
No new digest content identified.

 

IAVI [to 23 Nov 2019]
https://www.iavi.org/newsroom
Press Releases
November 18, 2019
Biofabri, IAVI, and SATVI Collaborate on Clinical Trial of TB Vaccine Candidate MTBVAC in South African Adults
Trial to evaluate safety, dosing, and immunogenicity of novel TB vaccine candidate
NEW YORK / PORRIÑO 19 NOVEMBER 2019 — Biofabri, IAVI, and the South African Tuberculosis Vaccine Initiative (SATVI) today announced an ongoing clinical trial to further evaluate the novel tuberculosis (TB) vaccine candidate MTBVAC in an adult endemic population…

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
No new digest content identified.

 

 

IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

 

IFRC [to 23 Nov 2019]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
No new digest content identified.

 

IVAC [to 23 Nov 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates
No new digest content identified.

 

IVI [to 23 Nov 2019]
http://www.ivi.int/
Selected IVI News & Announcements
No new digest content identified.

 

JEE Alliance [to 23 Nov 2019]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 23 Nov 2019]
http://www.msf.org/
Latest [Selected Announcements]
Somalia
From malnutrition to tuberculosis: responding to needs in North Gal…
Project Update 21 Nov 2019

Burundi
Cholera epidemic: “Thankfully, my family all came back cured”
Project Update 19 Nov 2019

Somalia
Floods leave thousands of people vulnerable and in need
Project Update 19 Nov 2019

 

National Vaccine Program Office – U.S. HHS [to 23 Nov 2019]
https://www.hhs.gov/vaccines/about/index.html
NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)

 

NIH [to 23 Nov 2019]
http://www.nih.gov/news-events/news-releases
Selected News Releases
No new digest content identified.

 

PATH [to 23 Nov 2019]
https://www.path.org/media-center/
Selected Announcements
No new digest content identified.

 

Sabin Vaccine Institute [to 23 Nov 2019]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 23 Nov 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
21 November 2019
Community groups delivering medicines in remote Central African Republic

19 November 2019
Jamaica: tackling HIV-related stigma and discrimination

18 November 2019
Sex workers often not accessing HIV prevention services

 

UNICEF [to 23 Nov 2019]
https://www.unicef.org/media/press-releases
Selected Statements, Press Releases, Reports
Press release
Geneva Palais briefing note on children in Syria
This is a summary of what was said by Fran Equiza, UNICEF Representative in Syria – to whom quoted text may be attributed – at today’s press briefing at the Palais des Nations in Geneva
21/11/2019

Statement
UNICEF welcomes renewed commitment to child rights, urges all Member States to leave no child behind
Statement by UNICEF Executive Director Henrietta Fore
20/11/2019

Statement
UNICEF Executive Director Henrietta Fore’s remarks at World Children’s Day 2019
20/11/2019

News note
News note on measles outbreaks across the Pacific Islands
SUVA, 19 November2019: UNICEF is supporting the Government of Samoa to respond to a measles outbreak in the country. The Government of Samoa officially declared a state of emergency on 15 November 2019, four weeks into the continuing measles outbreak with more than 1000 suspected cases so far. The epidemic has claimed the lives of 14 children under-five years old and one adult.
Measles outbreaks were also declared in the Kingdom of Tonga on 24 October and in Fiji on 7 November. As of 5 November, 177 cases have been confirmed in Tonga with no deaths. In Fiji, the four confirmed cases and one suspected case were contained in one specific area of Namosi and Serua Subdivision, west of the capital of Suva.
UNICEF has deployed health and communication staff in Samoa to boost the government’s immunization campaign and delivered a total of 110,500 doses of measles containing vaccines (100,000 MR and 10,500 MMR) and 30, 000 Vitamin A tablets. In addition, 6 refrigerators and three emergency response trolleys used as immunization service stations are being shipped to Samoa.
UNICEF has also delivered vaccines to Tonga, Fiji and Niue, and has worked with the governments of Vanuatu, Solomon Islands, Kiribati, Cook Islands, Niue, Marshall Islands and the Federated States of Micronesia (FSM) in conducting their measles immunization campaigns and developing their preparedness plans for an outbreak…

Press release
30 years of child rights: Historic gains and undeniable achievements, but little progress for the world’s poorest children
Urgent action and a recommitment to child rights needed to address age-old and emerging threats
17/11/2019

 

Vaccination Acceptance Research Network (VARN) [to 23 Nov 2019]
https://vaccineacceptance.org/news.html#header1-2r
No new digest content identified.

 

Vaccine Confidence Project [to 23 Nov 2019]
http://www.vaccineconfidence.org/
No new digest content identified.

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 23 Nov 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

 

Wellcome Trust [to 23 Nov 2019]
https://wellcome.ac.uk/news
Opinion | 21 November 2019
How we’re making our meetings more inclusive
by Charlie Gorham and Charlotte Hussey

 

The Wistar Institute [to 23 Nov 2019]
https://www.wistar.org/news/press-releases
No new digest content identified.

 

World Organisation for Animal Health (OIE) [to 23 Nov 2019]
https://www.oie.int/en/for-the-media/press-releases/2019/
No new digest content identified.

 

 

::::::

 

ARM [Alliance for Regenerative Medicine] [to 23 Nov 2019]
https://alliancerm.org/press-releases/
No new digest content identified.

 

BIO [to 23 Nov 2019]
https://www.bio.org/insights/press-release
No new digest content identified.

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 23 Nov 2019]
http://www.dcvmn.org/
News
No new digest content identified.

 

IFPMA [to 23 Nov 2019]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

 

PhRMA [to 23 Nov 2019]
http://www.phrma.org/
Selected Press Releases, Statements
Website not responding at inquiry.

 

 

Industry Watch
:: Takeda Presents 18-Month Data from Pivotal Phase 3 Trial of Dengue Vaccine Candidate at the American Society of Tropical Medicine and Hygiene (ASTMH) 68th Annual Meeting
− Data presented from the pivotal Phase 3 trial include an update on overall efficacy of the vaccine candidate, as well as formal analyses of secondary efficacy endpoints by serotype, baseline serostatus and disease severity −
− 18-month results build upon the efficacy and safety data reported in the 12-month analysis; overall vaccine efficacy remained generally consistent and the trial met all secondary endpoints for which there were a sufficient number of cases; safety and efficacy will be assessed over a total of four and a half years –
− Takeda presented 11 abstracts across its vaccine pipeline at ASTMH, including oral presentations on its dengue and Zika vaccine candidates −
November 23, 2019

:: WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland
DUNDALK, Ireland, Nov. 22, 2019 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development, and manufacturing, announced that its subsidiary WuXi Vaccines, engaged in human vaccine Contract Development and Manufacturing Organization (CDMO) business, is to invest 240 million USD and build a new vaccine manufacturing facility in Ireland. This investment follows the 20-year manufacturing Letter of Intent (LOI) signed by WuXi Vaccines earlier this year…

:: Advent International to acquire majority stake in Bharat Serums and Vaccines
Investment to strengthen and expand Bharat Serums’ offerings in India and global markets
Transaction is Advent’s seventh investment in the healthcare sector and fifth investment in India in 2019
MUMBAI, INDIA, November 18, 2019 – Advent International (“Advent”), one of the largest and most experienced global private equity investors, today announced that it has signed a definitive agreement to acquire a majority interest in Bharat Serums and Vaccines Limited (“Bharat Serums” or “BSV”), a biopharmaceutical leader in women’s healthcare, assisted reproductive treatment, critical care and emergency medicine in India and emerging markets…

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Development of a high number, high coverage dog rabies vaccination programme in Sri Lanka

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 23 Nov 2019)

 

Research article
Development of a high number, high coverage dog rabies vaccination programme in Sri Lanka
Rabies is estimated to cause 59,000 deaths and economic losses of US$8.6 billion every year. Despite several years of rabies surveillance and awareness programmes, increased availability of post-exposure proph…
Authors: Carlos Sánchez-Soriano, Andrew D. Gibson, Luke Gamble, Jordana L. Burdon Bailey, Samantha Green, Mark Green, Barend M. deC. Bronsvoort, Ian G. Handel, Richard J. Mellanby and Stella Mazeri
Citation: BMC Infectious Diseases 2019 19:977
Content type: Research article
Published on: 20 November 2019

Is selecting better than modifying? An investigation of arguments against germline gene editing as compared to preimplantation genetic diagnosis

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 23 Nov 2019)

 

Is selecting better than modifying? An investigation of arguments against germline gene editing as compared to preimplantation genetic diagnosis
Authors: Alix Lenia v. Hammerstein, Matthias Eggel and Nikola Biller-Andorno
Content type: Debate
21 November 2019

Interventions to improve human papillomavirus vaccination among Chinese female college students: study protocol for a randomized controlled trial

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 23 Nov 2019)

 

Study protocol
Interventions to improve human papillomavirus vaccination among Chinese female college students: study protocol for a randomized controlled trial
While the HPV vaccines have been approved by the US FDA since 2006, in recent years an increasing number of women are living with cervical cancer globally. Among them, Chinese women have a higher cervical canc…
Authors: Mingyu Si, Xiaoyou Su, Yu Jiang, Youlin Qiao and Yuanli Liu
Citation: BMC Public Health 2019 19:1546
Content type:
Published on: 21 November 2019

Including Pregnant Women in Clinical Research: Practical Guidance for Institutional Review Boards

Ethics & Human Research
Volume 41, Issue 6 November–December 2019
https://onlinelibrary.wiley.com/toc/25782363/current

 

Trial Design, Stakeholder Perspectives, Pregnancy and Research
Articles
Including Pregnant Women in Clinical Research: Practical Guidance for Institutional Review Boards
Pamela Payne
Pages: 35-40
First Published: 19 November 2019

Vaccination status of migrant populations in EU/EEA countries and implications for VPD control

The European Journal of Public Health
Volume 29, Issue Supplement_4, November 2019
https://academic.oup.com/eurpub/issue/29/Supplement_4

 

Supplement 12th European Public Health Conference Building bridges for solidarity and public health Marseille, France 20th–23rd November 2019
1.D. Global health and migration
Vaccination status of migrant populations in EU/EEA countries and implications for VPD control
S Hargreaves, J Himmels, L B Nellums, E McGuire, J S Friedland
Eur J Public Health, Volume 29, Issue Supplement_4, November 2019, ckz185.015, https://doi.org/10.1093/eurpub/ckz185.015

Building the capacity of users and producers of evidence in health policy and systems research for better control of endemic diseases in Nigeria: a situational analysis

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 23 Nov 2019]

Building the capacity of users and producers of evidence in health policy and systems research for better control of endemic diseases in Nigeria: a situational analysis
There is a current need to build the capacity of Health Policy and Systems Research + Analysis (HPSR+A) in low and middle-income countries (LMICs) as this enhances the processes of decision-making at all levels…
Authors: Obinna Onwujekwe, Enyi Etiaba, Chinyere Mbachu, Uchenna Ezenwaka, Ifeanyi Chikezie, Ifeyinwa Arize, Chikezie Nwankwor and Benjamin Uzochukwu
Content type: Research
21 November 2019

The State of Health Policy and Systems Research: Reflections From the 2018 5th Global Symposium

Health Policy and Planning
Volume 34, Issue Supplement_2, November 2019
https://academic.oup.com/heapol/issue/34/Supplement_2

 

SUPPLEMENT
Advancing health systems for all in the Sustainable Development Goal (SDG) era
Editorial
The State of Health Policy and Systems Research: Reflections From the 2018 5th Global Symposium
Kara Hanson, Kumanan Rasanathan, Asha George
Health Policy Plan, Volume 34, Issue Supplement_2, November 2019, Pages ii1–ii3, https://doi.org/10.1093/heapol/czz113
Health policy and systems research (HPSR) is now well-established as a field, facilitating interdisciplinary and engaged research and practice to strengthen health systems (de Savigny and Adam, 2009; Sheikh et al., 2011; Gilson 2012; Loewenson et al., 2014; George et al., 2017; Gilson et al., 2018), with growing understanding of its utility and value. One sign of its increasing strength is the continuing popularity of a regular ‘peak’ global event dedicated as a meeting space for exchange and dialogue across the diverse stakeholders critical to this field.

Assessment of vaccine wastage in an immunization clinic of a tertiary care hospital, Kolkata, West Bengal

International Journal of Community Medicine and Public Health
Vol 6, No 11 (2019) November 2019
https://www.ijcmph.com/index.php/ijcmph/issue/view/56

 

Original Research Articles
Assessment of vaccine wastage in an immunization clinic of a tertiary care hospital, Kolkata, West Bengal
Nabanita Chakraborty, Gautam Kumar Joardar
DOI: 10.18203/2394-6040.ijcmph20195088

Complexity in Assessing the Benefit vs Risk of Vaccines – Experience With Rotavirus and Dengue Virus Vaccines

JAMA
November 19, 2019, Vol 322, No. 19, Pages 1839-1932
http://jama.jamanetwork.com/issue.aspx

 

Viewpoint
Complexity in Assessing the Benefit vs Risk of Vaccines – Experience With Rotavirus and Dengue Virus Vaccines
H. Cody Meissner, MD
JAMA. 2019;322(19):1861-1862. doi:10.1001/jama.2019.16206
This Viewpoint uses experience with rotavirus vaccine–induced intussusception and dengue virus vaccine–induced shock syndrome to discuss issues of disease prevalence and severity underlying recommendations the vaccines be used widely, and it reviews the systems in place to monitor vaccine safety that broadly favor vaccine benefits over risks to individuals and society.

Human germline editing needs one message

Nature
Volume 575 Issue 7783, 21 November 2019
http://www.nature.com/nature/current_issue.html

 

Editorial | 20 November 2019
Human germline editing needs one message
Science academies and the World Health Organization must act in unison.
A year ago this week, geneticist He Jiankui made the shocking announcement of the birth of twin girls in China whose genomes had been edited to prevent HIV infection. Undeterred by the global opprobrium heaped on He, Russia’s Denis Rebrikov told Nature last month about more experiments involving gene editing of human eggs, to help deaf couples give birth to children who would lack the genetic mutation carried by their parents that impairs hearing.

At the same time, every month seems to bring another gene-editing advance. The latest tool, a precision ‘search and replace’ technique called prime editing, was described in Nature last month by David Liu at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, and his colleagues (A. V. Anzalone et al. Nature http://doi.org/dczp; 2019). Randall Platt at the Swiss Federal Institute of Technology (ETH) in Basel called it a “giant leap” towards the goal of making specific changes to the blueprint of life.

The speed of technological advance, coupled with some scientists’ determination to press ahead with editing human germline cells — eggs, sperm and embryonic cells — has been sounding alarm bells for nearly five years. Editing could produce unpredictable changes that an individual’s descendants will inherit — with potentially wide-reaching societal implications. Academies, governments and ethicists have been considering how to regulate this. But the manner in which it is being done is suboptimal.

In 2018, the World Health Organization (WHO) set up an independent expert panel to advise on the oversight and governance of human genome editing. A separate international commission on the clinical use of human germline genome editing gathered for its second meeting in London last week. This commission was established by the US National Academy of Science, the US National Academy of Medicine and Britain’s Royal Society, to recommend standards and criteria for germline genome editing. Both will report next year, and the commission’s report will feed into the WHO process.

But the WHO panel has already recommended setting up a public registry for genome-editing experiments. It has also made an interim recommendation that “it would be irresponsible at this time for anyone to proceed with clinical applications of human germline genome editing”, which has been accepted by the agency’s leadership. The international commission has yet to say what it thinks, but it would make little sense for it to disagree.

It isn’t entirely clear why separate initiatives are needed, and it is unfortunate that representatives of people with disabilities are not part of the decision-making process. However, it isn’t too late to rectify these issues, and the two initiatives must, in the end, converge.
There are very real risks that unregulated clinics claiming to be able to eliminate inherited conditions will use untested, possibly harmful procedures. A sure-fire way to give such clinics the green light is an absence of agreed global standards. When the two groups report next year, they must speak with one voice and have more inclusive representation.

Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents

New England Journal of Medicine
November 21, 2019 Vol. 381 No. 21
http://www.nejm.org/toc/nejm/medical-journal

 

Original Articles
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
S. Biswal and Others
…Conclusions
TAK-003 was efficacious against symptomatic dengue in countries in which the disease is endemic. (Funded by Takeda Vaccines; TIDES ClinicalTrials.gov number, NCT02747927)

Vaccination strategies to control Ebola epidemics in the context of variable household inaccessibility levels

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 23 Nov 2019)

 

Vaccination strategies to control Ebola epidemics in the context of variable household inaccessibility levels
Gerardo Chowell, Amna Tariq, Maria Kiskowski
Research Article | published 21 Nov 2019 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0007814
Author summary
In the context of the ongoing Ebola epidemic in DRC, active conflict and community distrust are undermining control efforts, including vaccination strategies. In this paper, we employed an individual-level stochastic structured transmission model to assess the impact of vaccination strategies on epidemic control in the context of variable levels of household inaccessibility. We found that a ring vaccination strategy of close contacts would not be effective for containing the epidemic in the context of significant delays to vaccinating contacts even for low levels of household inaccessibility and evaluate the impact of a supplemental community vaccination strategy. For lower levels of inaccessibility, the probability of epidemic containment increases over time. For higher levels of inaccessibility, even the combined ring and community vaccination strategies are not expected to contain the epidemic even though they help lower incidence levels, which saves lives, makes the epidemic easier to contain and reduces spread to other communities. We found that ring vaccination is effective for containing an outbreak until the levels of inaccessibility exceeds approximately 10%, a combined ring and community vaccination strategy is effective until the levels of inaccessibility exceeds approximately 50%. Our findings underscore the need to enhance community engagement to public health interventions.

Vaccine cold chain in general practices: A prospective study in 75 refrigerators (Keep Cool study)

PLoS One
http://www.plosone.org/
[Accessed 23 Nov 2019]

 

Research Article
Vaccine cold chain in general practices: A prospective study in 75 refrigerators (Keep Cool study)
Anika Thielmann, Marie-Therese Puth, Christine Kersting, Johannes Porz, Birgitta Weltermann
Research Article | published 19 Nov 2019 PLOS ONE
https://doi.org/10.1371/journal.pone.0224972

WHO Product Development for Vaccines Advisory Committee (PDVAC) – Associated R&D Activities

Vaccine
Volume 37, Issue 51 Pages 7451-7518 (3 December 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/51

 

Vaccine
Volume 37, Issue 50, Pages 7289-7450 (28 November 2019)
https://www.sciencedirect.com/journal/vaccine/vol/37/issue/50
WHO Product Development for Vaccines Advisory Committee (PDVAC) – Associated R&D Activities
Edited by B.K. Giersing, S.L. Gottlieb, J. Vekemans, G.A. Poland

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

Health Education & Behavior
First Published November 19, 2019
Characterizing HPV vaccine sentiments and content on Instagram
MD Kearney, P Selvan, MK Hauer, AE Leader…
Abstract
Background. With its growing popularity, inclusion of image and text, and user-friendly interface, Instagram is uniquely positioned for exploring health behaviors and sources and types of informational exposure related to the human papillomavirus (HPV) vaccine. Aims. To characterize public Instagram posts about the HPV vaccine and quantify the impact of sentiment and context on engagement via likes. Method. Using Netlytic, 3,378 publicly available English-language posts were collected using the search terms “#HPV,” “#HPVVaccine,” and “#Gardasil.” We randomly selected 1,200 posts to content analyze. Our final analytic sample included 360 posts after excluding posts whose links were no longer active (n = 221) or that were not relevant (n = 619). Results. A higher proportion of posts were pro-vaccine (55.8%) than anti-vaccine (42.2%). Pro-HPV vaccination posts were liked significantly less than anti-vaccination posts (24 vs. 86 likes; p < .001). More posts contained actionable information/resources (63.9%) than personal narrative elements (36.1%). Less than one in three posts (30.0%) came from health-related sources. Discussion. Pro-vaccine posts were more prevalent on Instagram, and anti-vaccine posts had higher engagement and typically included misleading information about the HPV vaccine. Personal narratives skewed toward anti-vaccine sentiments and most were produced by individual users. Pro-vaccine narratives portrayed individuals who received the vaccine, but provided limited details on vaccine experiences, starkly contrasting with the depth of details in anti-vaccine personal narrative posts. Conclusion. On Instagram, individuals and organizations have an opportunity to promote HPV vaccination by continuing to provide informational resources in addition to creating more narrative-style posts.

 

Innovation in Aging
2019 Nov; 3(Suppl 1): S809.
SHINGLES VACCINE UPTAKE AMONG OLDER ADULTS: IDENTIFYING EARLY, LATE, AND NON-ADOPTERS
H Kang, E Crimmins, JA Ailshire –
Abstract
Although a shingles vaccine (Zostavax) has been available since 2006, vaccination uptake has been slow. As a newly approved shingles vaccine (Shingrix) became available in 2018, understanding factors affecting acceptance and timing of the original vaccine would be useful in establishing effective strategies for greater immunization. Using the Health and Retirement study, we examined individual-level and area-level characteristics of early and late vaccine adopters, and those who were not vaccinated between 2006 and 2016. Early adopters were those who got vaccinated during the four year window after the approval of the vaccine; late vaccine adopters were those who got vaccinated from 2010 to 2016. Early adopters (13.5%) and late adopters (18.5%) comprised 32% of the sample, leaving two-thirds unvaccinated. Regression results suggest that those who received the vaccine were more likely to be socioeconomically advantaged, covered by insurance, socially active, healthy, to use other preventive vaccines, and to live in a region with more vaccinated people. Early adopters were more likely to be highly educated, affluent, and more conscientious compared to late adopters. Utilization of influenza vaccine and living in the region with the highest level of vaccination were found to be significant factors predicting early vaccine uptake. Our findings highlight the importance of outreach efforts and health care access in increasing vaccination rates.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 23 Nov 2019
[No new, unique, relevant content]

 

BBC
http://www.bbc.co.uk/
Accessed 23 Nov 2019
[No new, unique, relevant content]

 

The Economist
http://www.economist.com/
Accessed 23 Nov 2019
[No new, unique, relevant content]

 

Financial Times
http://www.ft.com/home/uk
Accessed 23 Nov 2019
[No new, unique, relevant content]

 

Forbes
http://www.forbes.com/
Accessed 23 Nov 2019
Nov 19, 2019
Bill Gates Is Both Chief Funder And Fundraiser In Polio Fight
The Bill and Melinda Gates Foundation in partnership with His Highness Sheikh Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi convened the “Reaching The Las Mile Forum” in Abu Dhabi today to announce total pledges of $2.6 billion to fight polio.
By Devin Thorpe Contributor

Nov 18, 2019
The States Where Vaccination Rates Are Falling [Infographic]
A new study from the Health Testing Centers has found that more than half of U.S. states experienced a decline in vaccination rates between 2009 and 2018.
By Niall McCarthy Contributor

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 23 Nov 2019
[No new, unique, relevant content]

Foreign Policy
http://foreignpolicy.com/
Accessed 23 Nov 2019
[No new, unique, relevant content]

 

The Guardian
http://www.guardiannews.com/
Accessed 23 Nov 2019
[No new, unique, relevant content]

 

New Yorker
http://www.newyorker.com/
Accessed 23 Nov 2019
[No new, unique, relevant content]

 

New York Times
http://www.nytimes.com/
Accessed 23 Nov 2019
Nov. 23
World
Samoa Measles Outbreak Kills 20, Mostly Children
Deaths related to measles, mostly among small children, have more than tripled to 20 in the past week on the Pacific island of Samoa, the government has said eight days after declaring a state of emergency over the outbreak.
By Reuters

 

Washington Post
https://www.washingtonpost.com/
Accessed 23 Nov 2019
[No new, unique, relevant content]

Think Tanks et al

Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 23 Nov 2019
[No new relevant content]

 

Center for Global Development
http://www.cgdev.org/page/press-center
Accessed 23 Nov 2019
[No new relevant content]

 

CSIS
https://www.csis.org/
Accessed 23 Nov 2019
[No new relevant content]

 

Council on Foreign Relations
http://www.cfr.org/
Accessed 23 Nov 2019
[No new relevant content]

 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=pre ss-release
[No new relevant content]

Vaccines and Global Health: The Week in Review :: 16 November 2019

.– Request an Email Summary: Vaccines and Global Health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

 pdf version A pdf of the current issue is available here: Vaccines and Global Health_The Week in Review_16 Nov 2019

– blog edition: comprised of the approx. 35+ entries posted below.

– Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
– Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy

EMA – First vaccine to protect against Ebola (updated) :: WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries :: Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union

Milestones :: Perspectives :: Research

 

EMA – First vaccine to protect against Ebola (updated)
CHMP, Last updated: 14/11/2019
EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation in the European Union for Ervebo (rVSVΔG-ZEBOV-GP), the first vaccine for active immunisation of individuals aged 18 years and older at risk of infection with the Ebola virus.

“This is an important step towards relieving the burden of this deadly disease,” said Guido Rasi, EMA’s Executive Director. “The CHMP’s recommendation is the result of many years of collaborative global efforts to find and develop new medicines and vaccines against Ebola. Public health authorities in countries affected by Ebola need safe and efficacious medicines to be able to respond effectively to outbreaks and save lives.”…

Ervebo is a genetically engineered, replication-competent, attenuated live vaccine. Data from clinical trials and compassionate use programs have shown that Ervebo protects against Ebola virus disease in humans following a single dose administration.

The clinical development of Ervebo was initiated in response to the 2014-2016 Ebola outbreak in cooperation with public health stakeholders, including national institutes of health, ministries of health in countries such as Guinea and DRC, WHO, the US Centers for Disease Control and Prevention, the Public Health Agency of Canada, Médecins Sans Frontières and others. In the ongoing Ebola outbreak in DRC, the vaccine is being used under an Expanded Access Protocol or ‘compassionate use’ to protect people at highest risk of infection such as healthcare workers, or people who have come into contact with infected patients or contacts of contacts according to a ring vaccination strategy.

Ervebo has been tested in approximately 16,000 individuals involved in several clinical studies in Africa, Europe and the United States where it has been proven to be safe, immunogenic (i.e. able to make the immune system respond to the virus) and effective against the Zaire Ebola virus that circulated in West Africa in 2014-2016. Preliminary data suggest that it is effective in the current outbreak in DRC. Additional efficacy and safety data are being collected through the Expanded Access Protocol and should be included in post-marketing safety reports, which are continuously reviewed by EMA.

Ervebo was supported through EMA’s PRIority MEdicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients’ unmet medical needs. Ervebo was granted eligibility to PRIME in June 2016 for active immunisation against Ebola…

 

::::::

WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries
12 November 2019 News release
The World Health Organization (WHO) today prequalified an Ebola vaccine for the first time, a critical step that will help speed up its licensing, access and roll-out in countries most at risk of Ebola outbreaks. This is the fastest vaccine prequalification process ever conducted by WHO.
Prequalification means that the vaccine meets WHO standards for quality, safety and efficacy. United Nations agencies and Gavi, the Vaccine Alliance, can procure the vaccine for at-risk countries based on this WHO recommendation.

“This is a historic step towards ensuring the people who most need it are able to access this life-saving vaccine,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Five years ago, we had no vaccine and no therapeutics for Ebola. With a prequalified vaccine and experimental therapeutics, Ebola is now preventable and treatable.”

The injectable Ebola vaccine, Ervebo, is manufactured by Merck (known as MSD outside the US and Canada). It has been shown to be effective in protecting people from the Ebola Zaire virus and is recommended by the WHO Strategic Advisory Group of Experts (SAGE) for vaccines as part of a broader set of Ebola response tools. The decision is a step towards greater availability of the vaccine in the future, though licensed doses will only be available mid-2020.

This announcement comes less than 48 hours after the European Commission decision to grant a conditional marketing authorization for the vaccine, following the recommendation from the European Medicines Agency (EMA)...

 

::::::

Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
:: Authorization Represents Significant Advancement in the Global Response to Ebola
:: Merck Remains Committed to Working with International Health Partners in Ebola Outbreak Response
November 11, 2019
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission has granted a conditional marketing authorization to ERVEBO for active immunization of individuals 18 years of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus. The use of ERVEBO should be in accordance with official recommendations. The approval is based on data submitted to the European Medicines Agency for accelerated assessment in March 2019. With this approval, the European Commission will grant a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members, Iceland, Liechtenstein and Norway. ERVEBO is currently under Priority Review with the U.S. Food and Drug Administration (FDA) with a target action date of March 14, 2020.

“The European Commission’s marketing authorization of ERVEBO is the result of an unprecedented collaboration for which the entire world should be proud. It is a historic milestone and a testament to the power of science, innovation and public-private partnership,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “After recognizing the need and urgency for an Ebola Zaire vaccine, many came together across sectors to answer the global call for outbreak preparedness. We at Merck are honored to play a part in Ebola outbreak response efforts and we remain committed to our partners and the people we serve. We also look forward to continuing to work with the FDA and the African countries on their regulatory reviews over the coming months and with the World Health Organization on vaccine prequalification, which will help broaden access to this important vaccine for those who need it most.”

Given the unique manufacturing requirements for ERVEBO, this approval allows Merck to initiate manufacturing of licensed doses in Germany, which are expected to start becoming available in the third quarter of 2020. Merck is also working closely with the World Health Organization (WHO), the United States Government, and Gavi, the Vaccine Alliance, to ensure uninterrupted access of its investigational Ebola Zaire vaccine (V920) in support of ongoing international response efforts in the DRC. As previously announced, Merck has committed to manufacture additional doses of investigational V920 over the coming year.

As part of its clinical development, and in response to requests from the WHO, Merck has, to date, donated more than 250,000 1.0mL doses of V920 to the WHO for use in outbreak response efforts occurring in the DRC since May 2018.

Merck has made a submission to the WHO seeking prequalification status for the vaccine, as well as submissions to selected African country National Regulatory Authorities in collaboration with the African Vaccine Regulatory Forum (AVAREF), which, if approved, will allow the vaccine to be registered in several African countries….

More People in the United States Dying from Antibiotic-Resistant Infections than Previously Estimated

More People in the United States Dying from Antibiotic-Resistant Infections than Previously Estimated
Wednesday, November 13, 2019

The Centers for Disease Control and Prevention (CDC) today released its updated Antibiotic Resistance Threats in the United States (AR Threats Report) indicating that antibiotic-resistant bacteria and fungi cause more than 2.8 million infections and 35,000 deaths in the United States each year. That means, on average, someone in the United States gets an antibiotic-resistant infection every 11 seconds and every 15 minutes someone dies. When Clostridioides difficile, a bacterium which is not typically resistant but can cause deadly diarrhea and is associated with antibiotic use, is added to these, the U.S. toll of all the threats in the report exceeds 3 million infections and 48,000 deaths.

Using data sources not previously available, the new report shows that there were nearly twice as many annual deaths from antibiotic-resistant infections as CDC originally reported in 2013. Since then, the new report shows, prevention efforts have reduced deaths from antibiotic-resistant infections by 18 percent overall and by nearly 30 percent in hospitals. Without continued vigilance, however, this progress may be challenged by the increasing burden of some infections.

CDC’s 2019 report thus establishes a new national baseline of infections and deaths from antibiotic-resistant germs. Moreover, the new report categorizes the top antibiotic-resistant threats based on level of concern to human health: urgent, serious, or concerning…

Vaccine-related advertising in the Facebook Ad Archive

Featured Journal Content

 

Vaccine
Available online 13 November 2019
In Press, Corrected Proof
Vaccine-related advertising in the Facebook Ad Archive
Amelia M.Jamison, David A.Broniatowski, Mark Dredze, ZachWood-Doughty Dure AdenKhan, Sandra Crouse Quinna
https://doi.org/10.1016/j.vaccine.2019.10.066Get rights and content
Highlights
:: First assessment of vaccine-related advertisements on Facebook Ad Archive.
:: Top pro-vaccine ad themes: vaccine promotion, philanthropy, news.
:: Top anti-vaccine ad themes: vaccine harm, promoting choice, uncovering “fraud”.
:: Two buyers accounted for majority (54%) of anti-vaccine advertising content.
:: Facebook policies negatively impact first time ad buyers, largely pro-vaccine.
Abstract
Background
In 2018, Facebook introduced Ad Archive as a platform to improve transparency in advertisements related to politics and “issues of national importance.” Vaccine-related Facebook advertising is publicly available for the first time. After measles outbreaks in the US brought renewed attention to the possible role of Facebook advertising in the spread of vaccine-related misinformation, Facebook announced steps to limit vaccine-related misinformation. This study serves as a baseline of advertising before new policies went into effect.
Methods
Using the keyword ‘vaccine’, we searched Ad Archive on December 13, 2018 and again on February 22, 2019. We exported data for 505 advertisements. A team of annotators sorted advertisements by content: pro-vaccine, anti-vaccine, not relevant. We also conducted a thematic analysis of major advertising themes. We ran Mann-Whitney U tests to compare ad performance metrics.
Results
309 advertisements were included in analysis with 163 (53%) pro-vaccine advertisements and 145 (47%) anti-vaccine advertisements. Despite a similar number of advertisements, the median number of ads per buyer was significantly higher for anti-vaccine ads. First time buyers are less likely to complete disclosure information and risk ad removal. Thematically, anti-vaccine advertising messages are relatively uniform and emphasize vaccine harms (55%). In contrast, pro-vaccine advertisements come from a diverse set of buyers (83 unique) with varied goals including promoting vaccination (49%), vaccine related philanthropy (15%), and vaccine related policy (14%).
Conclusions
A small set of anti-vaccine advertisement buyers have leveraged Facebook advertisements to reach targeted audiences. By deeming all vaccine-related content an issue of “national importance,” Facebook has further the politicized vaccines. The implementation of a blanket disclosure policy also limits which ads can successfully run on Facebook. Improving transparency and limiting misinformation should not be separate goals. Public health communication efforts should consider the potential impact on Facebook users’ vaccine attitudes and behaviors.

Emergencies

Emergencies

Ebola – DRC+
Public Health Emergency of International Concern (PHEIC)

Ebola Outbreak in DRC 67: 12 November 2019
1. Situation update
Over the last three months, there has been a steady decrease in confirmed cases of Ebola Virus Disease (EVD) in the Democratic Republic of the Congo. At the peak of the epidemic in the last week of April 2019, 120 cases were reported. In the week of 4 to 10 November 2019 only 12 cases were reported. Teams are building on this progress by enhancing efforts to thoroughly investigate all new cases and improving contact tracing in order to break the remaining transmission chains…

::::::
::::::

POLIO
Public Health Emergency of International Concern (PHEIC)

Polio this week as of 13 November 2019
:: Besides Acute Flaccid Paralysis surveillance and Environmental surveillance, how else do disease surveillance officers track the poliovirus in populated cities, hard-to-reach geographical areas and in conflict zones? Find out here.
:: With the current VDPV outbreaks in the Philippines, the Government with the support of GPEI and other partners is working hard to tackle the virus. The Government has pledged US$ 9 million in domestic resources and has to date disbursed US$ 6.7 million, complemented by contributions from the GPEI. Read the country’s latest situation report [below]

Summary of new viruses this week (AFP cases and ES positives):
:: Pakistan— two WPV1 cases, three WPV1-positive environmental samples, seven cVDPV2 cases and nine cVDPV2 positive environmental samples;
:: Nigeria – one cVDPV2 case;
:: Democratic Republic of the Congo (DR Congo)- eight cVDPV2 cases;
:: Angola— three cVDPV2 cases;
:: Chad— two cVDPV2 community contacts;
:: Côte d’Ivoire- one cVDPV2 positive environmental sample.

::::::

Weekly Epidemiological Record, 15 November 2019, vol. 94, 46 (pp. 525–540)
:: Progress towards poliomyelitis eradication – Pakistan, January 2018–September 2019
:: Update on vaccine-derived polioviruses – worldwide, January 2018–June 2019

::::::

Philippines
Situation Report 9 – Polio Outbreak
WHO-UNICEF 9 November 2019
Highlights
– 4th confirmed poliovirus type 2 case is a three-year old female from Maguindanao. Virus was found to be genetically linked to other 2 cases from Mindanao. Outbreak immunization for 18,268 children 0-59 months in the area was conducted on 4-8 November: 16,295 children (89.2%) vaccinated thus far.
– Synchronized polio vaccination campaigns on 14-27 October covered 1,628,717 children under 5: 95.5% of the target. Preparations ongoing for the next round on 25 November-7 December in National Capital Region (NCR) and all provinces of Mindanao targeting 4,388,281 children 0-59 months.
– Current polio outbreak resulting from persistently low routine immunization coverage, and poor sanitation and hygiene.
– Circulating vaccine-derived poliovirus (cVDPV) is considered a public health emergency of international concern (PHEIC).

… Risk assessment
The risk for further polio transmission in the country continues to be assessed as high at the national level, because of chronically suboptimal immunisation coverage, sub-optimal performance of AFP sur-veillance, and poor sanitation and hygiene conditions.
The regional risk of potential spread across international borders is assessed as moderate considering the large number of Overseas Filipino Workers (OFW). Although many OFW work globally, the risk of in-ternational spread is still considered low, but not negligible, further influenced by dynamic migratory patterns (particularly the USA).

… Immunization response
The first of three rounds of scheduled mass vaccination campaigns has been successfully implemented in polio affected areas. Between 14 and 27 October 2019, a total of 1,628,717 children under 5 were vac-cinated out of a targeted 1,703,639 in NCR, Davao del Sur, Davao City and Lanao del Sur. Both NCR and Davao City have reported reaching the target of 95% children vaccinated…

::::::

Editor’s Note:
WHO has posted a refreshed emergencies page which presents an updated listing of Grade 3,2,1 emergencies as below.

WHO Grade 3 Emergencies [to 16 Nov 2019]

Democratic Republic of the Congo
:: Ebola Outbreak in DRC 67: 12 November 2019

Mozambique floods – No new digest announcements identified
Nigeria – No new digest announcements identified
Somalia – No new digest announcements identified
South Sudan – No new digest announcements identified
Syrian Arab Republic – No new digest announcements identified
Yemen – No new digest announcements identified

::::::

WHO Grade 2 Emergencies [to 16 Nov 2019]

Afghanistan – No new digest announcements identified
Angola – No new digest announcements identified
Burkina Faso [in French] – No new digest announcements identified
Burundi – No new digest announcements identified
Cameroon – No new digest announcements identified
Central African Republic – No new digest announcements identified
Ethiopia – No new digest announcements identified
HIV in Pakistan – No new digest announcements identified
Iran floods 2019 – No new digest announcements identified
Iraq – No new digest announcements identified
Libya – No new digest announcements identified
Malawi floods – No new digest announcements identified
Measles in Europe – No new digest announcements identified
MERS-CoV – No new digest announcements identified
Myanmar – No new digest announcements identified
Niger – No new digest announcements identified
occupied Palestinian territory – No new digest announcements identified
Sudan – No new digest announcements identified
Ukraine – No new digest announcements identified
Zimbabwe – No new digest announcements identified

::::::

WHO Grade 1 Emergencies [to 16 Nov 2019]

Chad – No new digest announcements identified
Djibouti – No new digest announcements identified
Kenya – No new digest announcements identified
Mali – No new digest announcements identified
Namibia – viral hepatitis – No new digest announcements identified
Tanzania – No new digest announcements identified

::::::
::::::

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three ‘L3’ emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises. 
Syrian Arab Republic
:: Humanitarian Update Syrian Arab Republic – Issue 06 |14 November 2019
Response Efforts Increase in North-east Syria
The UN and its partners are working to address the needs of hundreds of thousands of people recently impacted by last month’s military escalation in north-east Syria.
Since Turkey’s military offensive began on 9 October, more than 190,000 women, children and men have been displaced. As of 12 November, more than 74,000 people remain displaced, including from Al-Hasakeh (48,134), Ar-Raqqa (19,471) and Aleppo (6,776) governorates. More than 14,000 people have reportedly fled to Iraq.
The fighting has seen civilian casualties in both Syria and Turkey, damage to and closure of critical infrastructure, including health and water treatment facilities, as well as significant forced displacement. At least 92 civilians have been killed in north-west and north-east Syria during these latest hostilities, according to the United Nations High Commissioner for Human Rights (OHCHR).
Of particular concern are threats to civilians and critical infrastructure, forced displacement of civilians within or outside Syria, the potential negative impact on essential services and livelihoods, as well as the obstruction of access for humanitarian assistance and protection services…

Yemen – No new digest announcements identified

::::::

UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.
Editor’s Note:
Ebola in the DRC has bene added as a OCHA “Corporate Emergency” this week:
CYCLONE IDAI and Kenneth
:: 13 Nov 2019 Southern Africa: 12 million people are food insecure
:: 12 November 2019 Southern Africa Humanitarian Snapshot (November 2019)

EBOLA OUTBREAK IN THE DRC – No new digest announcements identified

::::::
::::::

WHO & Regional Offices [to 16 Nov 2019]

WHO & Regional Offices [to 16 Nov 2019]
14 November 2019 News release
New report exposes horror of working conditions for millions of sanitation workers in the developing world

14 November 2019 News release
Mosquito sterilization offers new opportunity to control chikungunya, dengue, and Zika

13 November 2019 News release
WHO launches first-ever insulin prequalification programme to expand access to life-saving treatment for diabetes

12 November 2019 News release
WHO prequalifies Ebola vaccine, paving the way for its use in high-risk countries

 

::::::

Weekly Epidemiological Record, 15 November 2019, vol. 94, 46 (pp. 525–540)
:: Progress towards poliomyelitis eradication – Pakistan, January 2018–September 2019
:: Update on vaccine-derived polioviruses – worldwide, January 2018–June 2019

 

::::::

GIN October 2019 pdf, 2.29Mb 11 November 2019

 

::::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region AFRO
:: Democratic Republic of the Congo accelerates training of emergency medical units for…
14 November 2019 To efficiently provide treatment to people needing urgent medical care during epidemic situations, the Ministry of Health in the Democratic Republic of the Congo (DRC) and the World Health Organization (WHO) are this week training inaugural members of the country’s first national emergency medical units for epidemics.

WHO Region of the Americas PAHO
:: Dengue in the Americas reaches highest number of cases recorded (11/13/2019)
:: United Nations calls for urgent action to curb the rise in hunger and obesity in Latin America and the Caribbean (11/11/2019)

WHO South-East Asia Region SEARO
:: 14 November 2019 Statement To tackle diabetes, strengthen primary health care and empower families

WHO European Region EURO
:: Floods across Europe affect thousands 15-11-2019
:: Rapid HIV testing saves lives – it’s time to make the switch 11-11-2019

WHO Eastern Mediterranean Region EMRO
:: WHO remains vigilant in the detection, prevention and control of communicable diseases in Yemen 13 November 2019
:: US Department of State’s contribution boosts primary and referral health services for Syrian refugees in Iraq 13 November 2019

WHO Western Pacific Region
No new digest content identified.

CDC/ACIP [to 16 Nov 2019]

CDC/ACIP [to 16 Nov 2019]
http://www.cdc.gov/media/index.html
https://www.cdc.gov/vaccines/acip/index.html
Thursday, November 14, 2019
Transcript of November 13, 2019, AR Threats Report – Tele-briefing

Wednesday, November 13, 2019
More People in the United States Dying from Antibiotic-Resistant Infections than Previously Estimated
[See Milestones above for detail]

MMWR News Synopsis for Friday, November 15, 2019
Update on Vaccine-Derived Poliovirus Outbreaks — Worldwide, January 2018–June 2019
Stopping current outbreaks and limiting the risk of vaccine-derived poliovirus (VDPV) emergence requires increasing assistance to type-2-circulating VDPV outbreak countries; using a novel, stabilized monovalent type 2 oral polio virus in the future; maintaining high population immunity in all countries; and ending all live, attenuated oral poliovirus vaccine use after certification of polio eradication.
In under-immunized populations, strains of poliovirus in oral poliovirus vaccine (OPV) can circulate and mutate to behave like wild poliovirus, leading to outbreaks of paralytic poliomyelitis. During January 2018–June 2019, the number of circulating vaccine-derived poliovirus (cVDPV) outbreaks increased from nine to 29 during January 2017–June 2018. Of these, 86% were caused by cVDPV type 2 that occurred both inside and outside monovalent type 2 OPV outbreak response areas. Global OPV immunization after April 2016 only contained types 1 and 3 strains.

Progress Toward Poliomyelitis Eradication — Pakistan, January 2018–September 2019
Despite earlier progress, interruption of wild polio virus type 1 (WPV1) circulation in Pakistan failed in 2018-2019. Pakistan’s polio program has identified key gaps to address, including multiple managerial and operational challenges and reversing negative community perceptions of polio vaccination. Stopping WPV1 transmission in Pakistan will require sustained, quality implementation of eradication activities with a renewed sense of urgency.
Pakistan and Afghanistan are the only countries that continue to confirm ongoing wild poliovirus type 1 (WPV1) transmission. Despite reporting 12 cases in 2018, an increase to 80 cases as of Nov. 2019 shows that polio eradication efforts in Pakistan failed to interrupt transmission. The Pakistan Polio Eradication program has identified key gaps that need to be addressed, and national leadership has committed to making transformative changes. Pakistan’s program management, supervision and oversight in core transmission areas must be strengthened to support vaccination efforts and allow access to chronically missed children. Fully engaging communities and addressing resistance to vaccination will help rebuild trust and restore progress toward WPV1 elimination in Pakistan. WPV1 transmission can be interrupted in Pakistan, but it will require full and rapid implementation of recommendations.

China CDC

China CDC
http://www.chinacdc.cn/en/
No new digest content identified.

 

National Health Commission of the People’s Republic of China
http://en.nhc.gov.cn/
Selected Updates and Press Releases
Herder focus of hunt for plague source
2019-11-15
Health authorities in China are hunting down the source of a rare but fatal form of plague that infected a herding couple from the Inner Mongolia autonomous region and are stepping up
The two patients were recently taken from Inner Mongolia’s Xiliin Gol League to Beijing by ambulance to seek treatment and were diagnosed with pneumonic plague on Tuesday.
The capital’s Health Commission said in the early hours of Thursday that one patient was in stable condition while the other was “in critical condition but the symptoms had not deteriorated”…

Announcements

Announcements

 

Paul G. Allen Frontiers Group [to 16 Nov 2019]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
No new digest content identified.

 

BMGF – Gates Foundation [to 16 Nov 2019]
http://www.gatesfoundation.org/Media-Center/Press-Releases
No new digest content identified.

 

Bill & Melinda Gates Medical Research Institute [to 16 Nov 2019]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

 

CARB-X [to 16 Nov 2019]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

 

CEPI – Coalition for Epidemic Preparedness Innovations [to 16 Nov 2019]
http://cepi.net/
12 Nov 2019
Lassa Fever – an emerging disease we should look out for
By Erich Tauber
…Themis just announced the initiation of a Phase 1 clinical trial in healthy adult volunteers to investigate the safety, tolerability and immunogenicity of the MV-LASV vaccine candidate. MV-LASV was developed using a proprietary measles vector platform for prophylaxis of Lassa virus infection. What makes Themis’ technology unique is that the delivery vehicle that is used is the measles vaccine vector, which historically has a proven track-record of safety and potency as evidenced by the billions of people who have already been vaccinated world-wide. Themis applies this knowledge to develop innovative vaccine candidates including the one against Lassa fever…

 

Clinton Health Access Initiative, Inc. (CHAI) [to 16 Nov 2019]
https://clintonhealthaccess.org/about/
News & Press Releases
Clinton Health Access Initiative releases 2018 Annual Report
Published November 13th, 2019
…Highlights of this year’s report include:
– A breakthrough pricing agreement to significantly lower the cost of state-of-the-art diagnostic testing for HIV, hepatitis, and cervical cancer in low- and middle-income countries at a price of US$12 per patient sample.
– Expanding our integrated approach to maternal, newborn, and reproductive health to countries including Zambia, Uganda, and South Africa.
– A 58 percent reduction, on average, on the price of handheld pulse oximeters- simple, life-saving tools that can help to quickly diagnose severe pneumonia…

 

EDCTP [to 16 Nov 2019]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
12 November 2019
Novartis will support five Career Development Fellowships on maternal and child health
Novartis and EDCTP are pleased to highlight the sponsorship agreement to support research capacity development in sub-Saharan Africa. Within the framework of EDCTP’s 2019 Career Development Fellowships, Novartis will jointly fund fellows that aim to conduct research in the field…

 

Emory Vaccine Center [to 16 Nov 2019]
http://www.vaccines.emory.edu/
No new digest content identified.

 

European Medicines Agency [to 16 Nov 2019]
http://www.ema.europa.eu/ema/
News & Press Releases
Press release
First vaccine to protect against Ebola (updated)
CHMP, Last updated: 14/11/2019
[See Milestones above for detail]

 

European Vaccine Initiative [to 16 Nov 2019]
http://www.euvaccine.eu/news-events
No new digest content identified.

 

FDA [to 16 Nov 2019]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
No new digest content identified.

 

Fondation Merieux [to 16 Nov 2019]
http://www.fondation-merieux.org/
News, Events
December 3 – 4, 2019 – Geneva (Switzerland)
Mérieux Foundation co-organized event
6th GTFCC Working Group on Oral Cholera Vaccine

20 – 22 Jan 2020
Mérieux Foundation co-organized event
Dengue pre-vaccination screening strategies workshop
Les Pensières Center for Global Health, Veyrier-du-Lac (France)

 

Gavi [to 16 Nov 2019]
https://www.gavi.org/
Latest news
Pakistan becomes first country to introduce new typhoid vaccine into routine immunisation program  
15 November 2019
Gavi-supported introduction of new and improved typhoid conjugate vaccine to offer protection against increasingly drug-resistant disease.

New partnership launched to increase uptake of life-saving vaccines in Rwanda  
12 November 2019
Gavi, the Government of Rwanda and Girl Effect launch a 13-month partnership that will use innovative behaviour change communications to address gender related barriers to vaccine uptake.

Gavi welcomes European Commission approval of first Ebola vaccine  
12 November 2019
The European Commission has granted conditional marketing authorisation to the Ervebo Ebola vaccine in European Union member states.

 

GHIT Fund [to 16 Nov 2019]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.

 

Global Fund [to 16 Nov 2019]
https://www.theglobalfund.org/en/news/
News & Stories
News
Global Fund Board Steps Up Efforts to Expand Impact Against HIV, TB and Malaria
15 November 2019
… At the Board’s 42nd meeting, coming one month after a successful Sixth Replenishment that secured pledges of over US$14 billion for 2020-2022, Board members expressed appreciation for the collective efforts that led to such a strong mobilization of resources, calling it a compelling affirmation of commitment toward achieving greater social justice all over the world.
… The Board approved a decision that translates pledges made at the Replenishment Conference into funding for country allocations for the 2020-2022 period, as well as certain catalytic investments that can further enhance impact in priority areas. The Global Fund plans to finalize the allocation and inform countries in December 2019.
The Board also approved a decision to advance the development of wambo.org, an innovative online tool that gives in-country procurement teams the power to search, compare and purchase quality-assured products used by health programs. The Board’s decision allows wambo.org to be made available for non-Global Fund-financed orders by governments and nongovernment development organizations on a variety of products…

Updates
Donor Pledges and Contributions
12 November 2019
The Pledges and Contributions Report, a spreadsheet with a complete view of each donor’s pledges and contributions, is fully updated with Sixth Replenishment pledges and the dozens of new donors: Pledges and Contributions Report Excel | PDF

Sourcing & Management of Health Products
Opportunity for Evaluation of Diagnostic Products
11 November 2019
The Global Fund and Unitaid are inviting manufacturers of diagnostic products to submit an Expression of Interest to have their products evaluated by the Expert Review Panel for Diagnostics (EPRD).

 

Hilleman Laboratories [to 16 Nov 2019]
http://www.hillemanlabs.org/
No new digest content identified.

 

Human Vaccines Project [to 16 Nov 2019]
http://www.humanvaccinesproject.org/media/press-releases/
Press Releases
No new digest content identified.

 

IAVI [to 16 Nov 2019]
https://www.iavi.org/newsroom
Press Releases
November 12, 2019
Award from U.S. Department of Defense to Advance Marburg Virus Vaccine Candidate Development
Marburg virus has epidemic potential and is a high-priority agent that poses a national security threat
NEW YORK — NOVEMBER 12, 2019 — IAVI announced today the award of $35.7M from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to develop a recombinant vesicular stomatitis virus (VSV) vector Marburg virus vaccine candidate. This award builds on IAVI’s expertise in VSV vector technology that it has developed through its own VSV HIV vaccine candidate and VSV Lassa fever vaccine candidate, which are in preclinical development. The Marburg virus vaccine candidate, licensed by IAVI from the Public Health Agency of Canada, demonstrated strong protection from the deadly disease in non-human primate studies…

 

 

International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.

 

 

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
No new digest content identified.

 

 

IFFIm
http://www.iffim.org/library/news/press-releases/
No new digest content identified.

 

IFRC [to 16 Nov 2019]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
No new digest content identified.

 

IVAC [to 16 Nov 2019]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates
Report card on preventing global pneumonia and diarrhea deaths in children finds stalled progress
November 2019
The 10th annual Pneumonia & Diarrhea Progress Report Card from the International Vaccine Access Center highlights increases in immunization coverage but universal failure to meet targets in countries with the greatest burden of disease.

 

IVI [to 16 Nov 2019]
http://www.ivi.int/
Selected IVI News & Announcements
IVI to Accelerate Efforts in iNTS Vaccine Development
:: An award from the Wellcome Trust’s Affordable Innovations for Global Health Flagship will support IVI’s development and selection of potential vaccine candidates
:: There is currently no vaccine available to protect against invasive non-typhoidal salmonella (iNTS)
November 13, 2019 – SEOUL, South Korea – The International Vaccine Institute (IVI) has received a $3.33 million grant from the Wellcome Trust to identify and select promising vaccine candidates against invasive non-typhoidal salmonella (iNTS), an enteric disease that disproportionately affects the world’s poorest populations.
iNTS may cause up to 680,000 deaths every year, primarily in resource-poor settings in sub-Saharan Africa. Treatment is difficult and complicated by emerging antibiotic resistance, meaning therapeutic options are limited and expensive, if not inaccessible. With no vaccine currently available to prevent infection by these bacteria, IVI made a targeted investment in non-typhoidal Salmonella (NTS) vaccine development, anticipating a potential combination with IVI’s typhoid conjugate vaccine (TCV) that is now entering Phase III trials in Nepal, the Philippines and Indonesia. Going forward, this award from the Wellcome Trust will leverage that initial investment and help IVI accelerate vaccine development timelines and prepare for trials in humans.
“Developing a vaccine against invasive non-typhoidal Salmonella is a logical addition to our vaccine portfolio,” says Dr. Jerome Kim, Director General of IVI. “IVI’s efforts to reduce the burden of Salmonella Typhi date to the early 2000s when we first launched DOMI in Asia, and data collected in the past decade from Africa suggests that NTS disease is highly endemic in many African settings.”…

 

JEE Alliance [to 16 Nov 2019]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

 

MSF/Médecins Sans Frontières [to 16 Nov 2019]
http://www.msf.org/
Latest [Selected Announcements]
Statements and Press Releases
No new digest content identified.

 

National Vaccine Program Office – U.S. HHS [to 16 Nov 2019]
https://www.hhs.gov/vaccines/about/index.html
NVAC 2020 Meetings
February 13-14, 2020 NVAC Meeting
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)

 

NIH [to 16 Nov 2019]
http://www.nih.gov/news-events/news-releases
Selected News Releases
Thursday, November 14, 2019
NIH, NIST researchers use artificial intelligence for quality control of stem cell-derived tissues
Technique key to scale up manufacturing of therapies from induced pluripotent stem cells.

 

PATH [to 16 Nov 2019]
https://www.path.org/media-center/
Selected Announcements
PATH and partners receive award for development of world’s first malaria vaccine
November 13, 2019 by PATH
Pilot introduction of RTS,S/AS01 has now started in selected areas of three African countries
November 13, 2019, WASHINGTON, D.C. – PATH and partners today received the Global Health Technologies Coalition (GHTC) 2019 Innovating for Impact Partnership Award, for the development and phased introduction of RTS,S/AS01, the world’s first malaria vaccine. The vaccine was introduced by ministries of health in areas of Ghana, Kenya, and Malawi in 2019 as part of a pilot program coordinated by the World Health Organization (WHO).

The award was accepted by the director of PATH’s Malaria Vaccine Initiative, Dr. Ashley Birkett and Dr. Opokua Ofori-Anyinam, Director of Clinical Development at GSK Vaccines, at a recognition dinner at the Newseum in Washington, DC before an audience of US government officials, policymakers, media, and leaders in the global health and medical research communities. Drs. Birkett and Ofori-Anyinam accepted the award on behalf of all partners, including the Walter Reed Army Institute of Research and WHO.

The award is presented annually to an innovative product development partnership that has advanced a high-impact, game-changing global health technology. Honorees are chosen by a committee of global health experts.

“On behalf of PATH and all our partners in the development of RTS,S from around the world, we are honored to receive this award. We have worked with GSK Vaccines for almost 20 years, and we’re proud to have contributed to bringing this first malaria vaccine to children,” said Birkett. “This vaccine reflects PATH’s commitment to reducing the deadly toll of malaria among the most vulnerable–young children—even as we work towards the ultimate goal of eradicating malaria completely. We look forward to continuing to advance malaria vaccine development in support of that goal.”…

 

Sabin Vaccine Institute [to 16 Nov 2019]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.

 

UNAIDS [to 16 Nov 2019]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
14 November 2019
Pace of decline in new adult HIV infections remains short of ambition
The co-conveners of the Global HIV Prevention Coalition, UNAIDS and the United Nations Population Fund, have launched a new report on progress made in reducing new HIV infections across 28 countries that have been particularly affected by HIV. The report was launched at the High-Level Meeting of the Global HIV Prevention Coalition, held on 12 November on the sidelines of the Nairobi Summit on ICPD25.
Together, the 28 countries account for 75% of all new HIV infections globally—1.2 million of the 1.7 million new HIV infections among adults in 2018. The report, Implementation of the HIV prevention 2020 road map, shows that among the coalition countries new HIV infections among adults declined on average by 17% since 2010, slightly higher than the global decline of 13%, but far short of the 60% decline needed in 2018 to meet global HIV prevention targets…

13 November 2019
UNAIDS Executive Director holds first face-to-face meeting with key donors

12 November 2019
Statement of commitment to step up action towards ending AIDS, eliminate social injustice and reach the women and girls being left behind
This year marks the 25th anniversary of the International Conference on Population and Development (ICPD),  where 179 governments adopted a landmark Programme of Action. The Programme of Action unequivocally affirmed reproductive rights as human rights, fundamental to the empowerment of women and girls and to achieving gender equality and sustainable development more broadly.
From 12 to 14 November, the governments of Kenya and Denmark, together with the United Nations Population Fund (UNFPA), are co-convening the Nairobi Summit to mobilize the political will and financial commitments needed to finally and fully implement the Programme of Action…

12 November 2019
The power of transgender visibility in Jamaica

12 November 2019
HIV-related discrimination far too high

 

UNICEF [to 16 Nov 2019]
https://www.unicef.org/media/press-releases
Selected Statements, Press Releases, Reports
Press release 11/11/2019
One child dies of pneumonia every 39 seconds, agencies warn
Pneumonia – a preventable disease – kills more children than any other infection

 

Vaccination Acceptance Research Network (VARN) [to 16 Nov 2019]
https://vaccineacceptance.org/news.html#header1-2r
No new digest content identified.

 

Vaccine Confidence Project [to 16 Nov 2019]
http://www.vaccineconfidence.org/
Blog
VACCINES & FAKE NEWS: Analysing measles outbreaks 2019
Posted on 10 Nov, 2019
By  Lola García-Ajofrín
Even though it is a vaccine-preventable disease, measles kills over 100,000 people every year. Worldwide cases tripled in the first three months of 2019. The causes of these outbreaks are diverse: from health infrastructure to civil

 

Vaccine Education Center – Children’s Hospital of Philadelphia [to 16 Nov 2019]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

 

Wellcome Trust [to 16 Nov 2019]
https://wellcome.ac.uk/news
Opinion | 14 November 2019
Landmark moment in the fight against Ebola: what have we learnt?
by Charlie Weller

Opinion | 13 November 2019
With better global data we can outsmart drug-resistant infections
by Gemma Buckland Merrett
The impact of drug-resistant infections is much higher than previously thought, as shown in a new report from the Centers for Disease Control.

Opinion | 12 November 2019
Does the way Wellcome makes funding decisions support the right research?
by Jonathan Best

 

The Wistar Institute [to 16 Nov 2019]
https://www.wistar.org/news/press-releases
Press Release Nov. 14, 2019
International Collaboration for Scientific Training Launched Between The Wistar Institute and Leiden University Medical Center in the Netherlands
Wistar and Leiden University Medical Center (LUMC) formalized a memorandum of understanding between the two institutions to explore a postdoctoral training exchange program in immunology, cancer research and vaccine biology.

 

World Organisation for Animal Health (OIE) [to 16 Nov 2019]
14/11/19
A new OIE Sub Regional Representation for Middle East opens in United Arab Emirates
On the occasion of the 15th Conference of the OIE Regional Commission for the Middle East, the OIE officially opens its Sub Regional Representation for Middle East in United Arab Emirates. This new office will strengthen the region’s cooperation with the OIE and among its Members thereby addressing their main concerns, such as the control of transboundary animal diseases, including zoonoses, and animal welfare in particular in the context of trade purposes.

 

 

::::::

 

ARM [Alliance for Regenerative Medicine] [to 16 Nov 2019]
https://alliancerm.org/press-releases/
No new digest content identified.

 

BIO [to 16 Nov 2019]
https://www.bio.org/insights/press-release
No new digest content identified.

 

DCVMN – Developing Country Vaccine Manufacturers Network [to 16 Nov 2019]
http://www.dcvmn.org/
News
WHO Director General addressed the delegates of the DCVMN Annual General Meeting 2019
Rio de Janeiro, 22nd October 2019 – On the occasion of the 20th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN), held on Brazil, WHO Director General, Dr. Tedros Ghebreyesus, addressed the delegates by video. He highlighted that “vaccines are one of the most accessible and cost-effective tools in the history of healthcare. Smallpox has been eradicated, polio is on the brink, and millions of lives have been saved from measles, meningitis and other diseases thanks to vaccines.” However, many children are missing out vaccination and preventable diseases are still a major cause of illness and death. Low and middleincome countries have been slower in adopting vaccines than high-income countries, and one of the barriers has been the lack of resources and regulatory systems.

The DCVMN members have made a vital contribution to increasing the quality, availability and affordability of vaccines. There are now over 70 WHO prequalified vaccines from DCVMN members, including rotavirus, yellow fever, cholera and more, he mentioned.

He added that “our next challenge is to use collaborative ways to translate these vaccines availability into national licences for use in countries. Low resources, heavy workload and untrained staff in many countries mean that vaccines take longer to reach children.” He thanked DCVMN and all its Partners, Gavi, UNICEF, BMGF and others, for their support and commitment. “Together we can overcome the barriers we face, and ensure that all children enjoy the lifesaving power of vaccines” he concluded.

 

IFPMA [to 16 Nov 2019]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

 

PhRMA [to 16 Nov 2019]
http://www.phrma.org/
Selected Press Releases, Statements
Website not responding at inquiry.

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focu-s on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Can we make human plague history? A call to action

BMJ Global Health
November 2019 – Volume 4 – 6
https://gh.bmj.com/content/4/6

 

Can we make human plague history? A call to action (10 November, 2019)
Laurence Baril, Xavier Vallès, Nils Christian Stenseth, Minoarisoa Rajerison, Maherisoa Ratsitorahina, Javier Pizarro-Cerdá, Christian Demeure, Steve Belmain, Holger Scholz, Romain Girod, Joseph Hinnebusch, Ines Vigan-Womas, Eric Bertherat, Arnaud Fontanet, Yazdan Yazadanpanah, Guia Carrara, Jane Deuve, Eric D’ortenzio, Jose Oswaldo Cabanillas Angulo, Paul Mead, Peter W Horby

Joint external evaluation of the International Health Regulation (2005) capacities: current status and lessons learnt in the WHO African region

BMJ Global Health
November 2019 – Volume 4 – 6
https://gh.bmj.com/content/4/6

 

Analysis
Joint external evaluation of the International Health Regulation (2005) capacities: current status and lessons learnt in the WHO African region (1 November, 2019)
Ambrose Talisuna, Ali Ahmed Yahaya, Soatiana Cathycia Rajatonirina, Mary Stephen, Antonio Oke, Allan Mpairwe, Amadou Bailo Diallo, Emmanuel Onuche Musa, Daniel Yota, Freddy Mutoka Banza, Roland Kimbi Wango, Nathalie Amy Roberts, Rajesh Sreedharan, Nirmal Kandel, Adrienne May Rashford, Linda Lucy Boulanger, Qudsia Huda, Stella Chungong, Zabulon Yoti, Ibrahima Soce Fall

BCG vaccination is associated with reduced malaria prevalence in children under the age of 5 years in sub-Saharan Africa

BMJ Global Health
November 2019 – Volume 4 – 6
https://gh.bmj.com/content/4/6

 

Research
BCG vaccination is associated with reduced malaria prevalence in children under the age of 5 years in sub-Saharan Africa (14 November, 2019)
Mike LT Berendsen, Sjors WL van Gijzel, Jeroen Smits, Quirijn de Mast, Peter Aaby, Christine S Benn, Mihai G Netea, Andre JAM van der Ven

Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 16 Nov 2019)

 

Research article
Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County
Identification and knowledge of settings with high prevalence of hepatitis C virus (HCV) infection is important when aiming for elimination of HCV. The primary aim of this study was to estimate the prevalence …
Authors: Caroline Gahrton, Gabriel Westman, Karin Lindahl, Fredrik Öhrn, Olav Dalgard, Christer Lidman, Lars-Håkan Nilsson, Karouk Said, Ann-Sofi Duberg and Soo Aleman
Citation: BMC Infectious Diseases 2019 19:955
Content type: Research article
Published on: 9 November 2019

Compensation of subjects for participation in biomedical research in resource – limited settings: a discussion of practices in Malawi

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 16 Nov 2019)

 

Compensation of subjects for participation in biomedical research in resource – limited settings: a discussion of practices in Malawi
Compensating participants of biomedical research is a common practice. However, its proximity with ethical concerns of coercion, undue influence, and exploitation, demand that participant compensation be regulated. The objective of this paper is to discuss the current regulations for compensation of research participants in Malawi and how they can be improved in relation to ethical concerns of coercion, undue influence, and exploitation.
Authors: Wongani Nyangulu, Randy Mungwira, Nginanche Nampota, Osward Nyirenda, Lufina Tsirizani, Edson Mwinjiwa and Titus Divala
Content type: Debate
14 November 2019

Hospital discharges-based search of acute flaccid paralysis cases 2007–2016 in Italy and comparison with the National Surveillance System for monitoring the risk of polio reintroduction

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 Nov 2019)

 

Research article
Hospital discharges-based search of acute flaccid paralysis cases 2007–2016 in Italy and comparison with the National Surveillance System for monitoring the risk of polio reintroduction
Acute flaccid paralysis (AFP) surveillance has been adopted globally as a key strategy for monitoring the progress of the polio eradication initiative. Hereby, to evaluate the completeness of the ascertainment…
Authors: Paola Stefanelli, Stefania Bellino, Stefano Fiore, Stefano Fontana, Concetta Amato and Gabriele Buttinelli
Citation: BMC Public Health 2019 19:1532
Content type: Research article
Published on: 15 November 2019

Research protocol of two concurrent cluster-randomized trials: Real-life Effect of a CAMPaign with Measles Vaccination (RECAMP-MV) and Real-life Effect of a CAMPaign with Oral Polio Vaccination (RECAMP-OPV) on mortality and morbidity among children in rural Guinea-Bissau

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 Nov 2019)

 

Research protocol of two concurrent cluster-randomized trials: Real-life Effect of a CAMPaign with Measles Vaccination (RECAMP-MV) and Real-life Effect of a CAMPaign with Oral Polio Vaccination (RECAMP-OPV) on mortality and morbidity among children in rural Guinea-Bissau
Measles and oral polio vaccinations may reduce child mortality to an extent that cannot be explained by prevention of measles and polio infections; these vaccines seem to have beneficial non-specific effects. …
Authors: A. Varma, A. K. G. Jensen, S. M. Thysen, L. M. Pedersen, P. Aaby and A. B. Fisker
Citation: BMC Public Health 2019 19:1506
Content type: Study protocol
Published on: 11 November 2019

A systematic review of BCG vaccination policies among high-risk groups in low TB-burden countries: implications for vaccination strategy in Canadian indigenous communities

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 16 Nov 2019)

 

A systematic review of BCG vaccination policies among high-risk groups in low TB-burden countries: implications for vaccination strategy in Canadian indigenous communities
Bacille Calmette-Guérin (BCG) vaccination against tuberculosis (TB) is widespread in high-TB-burden countries, however, BCG vaccination policies in low-burden countries vary. Considering the uncertainties surr…
Authors: Lena Faust, Yoko Schreiber and Natalie Bocking
Citation: BMC Public Health 2019 19:1504
Content type: Research article
Published on: 11 November 2019

Optimization of extraction of genomic DNA from archived dried blood spot (DBS): potential application in epidemiological research & bio banking

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 16 Nov 2019]

 

Research Article
Revised
Optimization of extraction of genomic DNA from archived dried blood spot (DBS): potential application in epidemiological research & bio banking [version 3; peer review: 2 approved with reservations]
Abhinendra Kumar, Sharayu Mhatre, Sheela Godbole, Prabhat Jha, Rajesh Dikshit
Limited infrastructure is available to collect, store and transport venous blood in field epidemiological studies. Dried blood spot (DBS) is a robust potential alternative sample source for epidemiological studies & bio banking. A stable source of genomic DNA (gDNA) is required for long term storage in bio bank for its downstream applications. Our objective is to optimize the methods of gDNA extraction from stored DBS and with the aim of revealing its utility in large scale epidemiological studies.

Immunization Status at the Time of Liver Transplant in Children and Adolescents

JAMA
November 12, 2019, Vol 322, No. 18, Pages 1731-1836
http://jama.jamanetwork.com/issue.aspx

 

Research Letter
Immunization Status at the Time of Liver Transplant in Children and Adolescents
Amy G. Feldman, MD, MSCS; Shikha S. Sundaram, MD, MSCI; Brenda L. Beaty, MSPH; et al.
JAMA. 2019;322(18):1822-1824. doi:10.1001/jama.2019.14386
This study characterizes the percentage of pediatric patients undergoing liver transplant who were up to date for their age on immunizations at the time of transplant and risk factors for underimmunization.

Heritable Genome Editing—Edited Eggs and Sperm to the Rescue?

JAMA
November 12, 2019, Vol 322, No. 18, Pages 1731-1836
http://jama.jamanetwork.com/issue.aspx

 

The JAMA Forum
Heritable Genome Editing—Edited Eggs and Sperm to the Rescue?
Eli Adashi, MD, MS; I. Glenn Cohen, JD
free access
JAMA. 2019;322(18):1754-1755. doi:10.1001/jama.2019.17538
Heritable genome editing is widely predicted to render inborn afflictions a thing of the past. Topping the list of edit-worthy maladies are single-gene disorders for which preimplantation genetic diagnosis is unworkable. In addition, an insufficient number of viable embryos without the disease mutation is an important limitation in preimplantation genetic diagnosis, and in such cases, heritable genome editing might offer an alternative strategy.

Constraints along these lines have frequently undermined some families’ attempts to have a baby—a “savior sibling”—who could serve as a stem cell donor to a sick older sibling who might benefit. Heritable genome editing could also be brought to bear on disease-predisposing gene variants, such as a variant of the APOE gene that contributes to Alzheimer disease risk; a variant of the LPA gene that contributes to atherosclerotic cardiovascular disease; a variant of the MYPBC3 gene that causes hypertrophic cardiomyopathy; and variants in BRCA genes that increase breast and ovarian cancer risk. Currently, the focus of preclinical research, with safety and efficacy in mind, heritable genome editing remains years away from the clinic.

Preclinical research efforts to replace mutant alleles with wild-type counterparts have thus far been limited to human embryos. Such efforts have formidable technical challenges, including introduction of unintended genomic insertions, deletions, and rearrangements, which cannot be tolerated in the clinical context. Nothing less than unyielding editing precision is required to preclude cross-generational harm. An additional challenge to editing the human embryo is the uniformity imperative—ensuring that all the embryo’s cells are appropriately edited. Failure to edit the entire cellular complement of the embryo to exclude mosaicism (in this case, a mixture of edited and unedited cells) is clinically inviable. One final challenge of note is the required validation of edited embryos as transfer eligible. Impeccable editing fidelity as well as uniformity must be documented prior to embryo transfer. At present, however, such reliable assessment is technologically infeasible, and accomplishing this goal may require new technologies.

Apart and distinct from the technical hurdles, editing the genome of the human embryo is also subject to political and doctrinal opposition, which likely gave rise to the statutory federal moratorium now in effect. Under the Consolidated Appropriation Act of 2016, the moratorium prohibits the US Food and Drug Administration from addressing research “in which a human embryo is intentionally created or modified to include heritable genetic modification.”

Expounding on the bill in question, Rep Harold D. Rogers (R, Kentucky) noted that it “preserves the sanctity of life,” adding “new provisions prohibiting genetic editing of human embryos.” Rep Robert B. Aderholt (R, Alabama) said that “prohibition on gene editing of human embryos…is a tremendous victory for those who are concerned about life.” Given that the prospect of editing of the human embryo genome is caught up in the debate over abortion, proponents of gene editing will be hard-pressed to secure the broad political support required for its actualization.

In light of such technical, political, as well as doctrinal challenges, genomic editing in the human embryo thus faces an uphill struggle, and it is against this backdrop that the possibility of editing human eggs or sperm first came to the fore. Given that the editing of eggs and sperm is not mentioned in the statutory federal moratorium, limited political and doctrinal opposition to this approach may be assumed. An additional advantage of this tack is that it avoids the possibility of embryonic mosaicism. The feasibility of assessing the quality of the editing process constitutes yet another upside.

During the 2015 International Summit on Human Gene Editing, scientists reported that editing of mouse spermatogonial stem cells corrected a cataract-causing mutation. Further progress, however, has been sparse. Held back by the requisite testicular transplanting of edited spermatogonial stem cells, only a limited body of experimental work followed. There has been a comparably modest body of work dedicated to the editing of maturing eggs.

The successful editing of human gametes, it would seem, may have to await the materialization of a rapidly evolving scientific field, in vitro gametogenesis (IVG), which is poised to convert somatic cells (such as skin) to induced pluripotent stem cells, and thereupon to mature eggs or sperm. Editing of IVG-derived egg or sperm precursors and their validation by whole-genome sequencing should prove eminently feasible. Correctly edited clones of eggs or sperm could then be selected for eventual use during in vitro fertilization. At this point, scientists have generated human primordial germ cell-like cells and o oogonia in vitro. However, the in vitro reconstitution of the entire cycle of the human germline remains to be accomplished. Given the anticipated advantages of editing the genome of IVG-generated human eggs or sperm, this innovation may well be worth the wait.
[References at title link above]

The 2019 report of The Lancet Countdown on health and climate change: ensuring that the health of a child born today is not defined by a changing climate

The Lancet
Nov 16, 2019 Volume 394Number 10211p1779-1878, e36
https://www.thelancet.com/journals/lancet/issue/current

 

Review
The 2019 report of The Lancet Countdown on health and climate change: ensuring that the health of a child born today is not defined by a changing climate
Nick Watts, et al
From Executive Summary
The Lancet Countdown is an international, multidisciplinary collaboration, dedicated to monitoring the evolving health profile of climate change, and providing an independent assessment of the delivery of commitments made by governments worldwide under the Paris Agreement.
The 2019 report presents an annual update of 41 indicators across five key domains: climate change impacts, exposures, and vulnerability; adaptation, planning, and resilience for health; mitigation actions and health co-benefits; economics and finance; and public and political engagement. The report represents the findings and consensus of 35 leading academic institutions and UN agencies from every continent. Each year, the methods and data that underpin the Lancet Countdown’s indicators are further developed and improved, with updates described at each stage of this report. The collaboration draws on the world-class expertise of climate scientists; ecologists; mathematicians; engineers; energy, food, and transport experts; economists; social and political scientists; public health professionals; and doctors, to generate the quality and diversity of data required…

WHO sticks to 2020 governance plan for human-genome editing

Nature
Volume 575 Issue 7782, 14 November 2019
http://www.nature.com/nature/current_issue.html

 

CORRESPONDENCE
12 November 2019
WHO sticks to 2020 governance plan for human-genome editing
Margaret Hamburg & Edwin Cameron
The turmoil around plans from Russia for gene editing of human embryos (see Nature 574, 465–466; 2019) underscores the importance and urgency of the global governance framework now being developed by the World Health Organization’s expert advisory committee on human genome editing (go.nature.com/33j6q1s). Before the end of 2020, we aim to identify the key issues and to make solutions scalable, sustainable and appropriate for use at international, regional, national and local levels.

Our efforts are grounded in transparency, inclusivity, fairness, responsible scientific stewardship and social justice. To meet these criteria, we aim to share information on the committee’s own processes and outcomes, on what is happening and on how and why it is necessary; we will draw on contributions from all parts of global society to provide diverse viewpoints; we will adhere to good practice in scientific and clinical conduct, maximizing benefits and minimizing harm; and our dealings will allow everyone equal access to opportunities and potential benefits.

We reject all forms of discrimination based on personal or group characteristics, including gender, race, ethnicity, sexuality, age and disability. We are exploring how we can expand the views and perspectives that feed into our work, aiming for effective public and community engagement in developing governance mechanisms for human-genome editing.

Understanding the rise of cardiometabolic diseases in low- and middle-income countries

Nature Medicine
Volume 25 Issue 11, November 2019
https://www.nature.com/nm/volumes/25/issues/11

 

Review Article | 07 November 2019
Understanding the rise of cardiometabolic diseases in low- and middle-income countries
The rise of cardiometabolic diseases in low- and middle-income countries is tied to a multitude of environmental, social and commercial determinants, which are discussed in this Review along with a strategy to counteract those factors.
J. Jaime Miranda, Tonatiuh Barrientos-Gutiérrez[…] & Jonathan C. K. Wells